The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An open-label positron emission tomography (PET) study to investigate and quantify brain and tumor penetration of carbon-11 labeled lapatinib in patients with HER2-overexpressing (HER2+) advanced or metastatic breast cancer (MBC).
R. C. Coombes
No relevant relationships to disclose
J. A. Reise
No relevant relationships to disclose
M. Lau
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
S. C. Carme
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
G. E. Searle
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
M. Huiban
Employment or Leadership Position - GlaxoSmithKline
P. Burgess
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
K. Koch
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
A. Das-Gupta
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
A. Saleem
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline